Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk
作者:
M. Stahl,
H. Wilke,
P. Preusser,
U. Fink,
W. Achterrath,
C. Schöber,
C.H. Köhne-Wömpner,
A. Harstrick,
H.J. Meyer,
J. Meyer,
L. Lenaz,
H.J. Schmoll,
期刊:
Onkologie
(Karger Available online 1991)
卷期:
Volume 14,
issue 4
页码: 314-318
ISSN:0378-584X
年代: 1991
DOI:10.1159/000216998
出版商: S. Karger GmbH
关键词: Advanced gastric carcinoma;Etoposide;Leukovorin and 5-Fluorouracil;Elderly patients
数据来源: Karger
摘要:
Combination chemotherapy with etoposide, leucovorin and 5-FU (ELF) was investigated in a phase-II study in patients with advanced gastric carcinoma (stage III and IV). Only ambulatory patients (performance status WHO ≤2) above 65 years or younger patients with cardiac disease were entered. A remission rate of 53% could be achieved in 51 evaluable patients, including 12% complete remissions. One toxic death was observed. Remission rate was particularly high in patients with locally advanced disease (70%, 7/10 patients). Median remission duration was 8 months, median overall survival 11.5 months. Patients with peritoneal carcinosis lived significantly shorter than those with other distant metastases (P < 0.05). ELF was well tolerable. The efficacy of ELF, combined with its moderate toxicity, make this therapy a useful approach in the treatment of gastric cancer, where treatment intention is palliative so fa
点击下载:
PDF
(2060KB)
返 回